Yusuke Hamakawa
Overview
Explore the profile of Yusuke Hamakawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamakawa Y, Hirahara A, Hayashi A, Ito K, Shinohara H, Shiba A, et al.
BMC Cancer
. 2025 Jan;
25(1):17.
PMID: 39762819
Introduction: The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune...
2.
Taniguchi Y, Shigenobu T, Hayashi A, Hirahara A, Ito K, Shinohara H, et al.
Anticancer Res
. 2024 Dec;
44(12):5541-5549.
PMID: 39626937
Background/aim: Survival outcomes in patients with successfully resected non-small-cell lung cancer (NSCLC) are not well understood. Furthermore, the best treatment strategy for postoperative locoregional recurrence has not been established. Patients...
3.
Aga M, Okubo S, Ikeda T, Higashi Y, Hamakawa Y, Matsuzaka S, et al.
J Med Case Rep
. 2024 Jul;
18(1):318.
PMID: 38997782
Background: Cold agglutination syndrome is a subtype of autoimmune hemolytic anemia. The condition is referred to as "cold" because the antibodies become active and induce hemolysis at cold temperatures, typically...
4.
Kurosawa S, Hamakawa Y, Yoshimura Y, Hayashi H, Nakazato T, Okamoto H
Lancet Haematol
. 2024 Feb;
11(2):e168.
PMID: 38302224
No abstract available.
5.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, et al.
Jpn J Clin Oncol
. 2024 Jan;
54(4):452-462.
PMID: 38271158
Objective: As first-line treatment for stage IV or recurrent non-small cell lung cancer, combination immunotherapy with nivolumab and ipilimumab, with or without chemotherapy, had demonstrated survival benefits over chemotherapy; however,...
6.
Sawada H, Taniguchi Y, Iizuka S, Ikeda T, Aga M, Hamakawa Y, et al.
Case Rep Oncol
. 2023 Dec;
16(1):1558-1567.
PMID: 38089732
Introduction: C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1-2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known...
7.
Hamakawa Y, Agemi Y, Shiba A, Ikeda T, Higashi Y, Aga M, et al.
Cancer Med
. 2023 Aug;
12(17):17788-17797.
PMID: 37548381
Background: The relationship between epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance, including osimertinib, and programmed cell death-ligand 1 (PD-L1) expression status in EGFR-mutated non-small cell lung carcinoma (NSCLC)...
8.
Miyazaki K, Shiba A, Ikeda T, Higashi Y, Aga M, Hamakawa Y, et al.
BMC Cancer
. 2022 Sep;
22(1):977.
PMID: 36100844
Background: Granulocyte colony-stimulating factor (G-CSF)-producing lung cancer induces severe inflammation and a high white blood cell (WBC) count and is associated with poor prognosis. A recent case of G-CSF-producing lung...
9.
Fukasawa N, Agemi Y, Shiba A, Aga M, Hamakawa Y, Miyazaki K, et al.
Respirol Case Rep
. 2022 Aug;
10(9):e01004.
PMID: 35950141
Malignant pericardial mesothelioma (MPM) is a rare tumour that arises from the mesothelial cells of the pericardium. No standard treatment has been established owing to a poor treatment response; therefore,...
10.
Miyazaki K, Yoshimura Y, Miyata N, Sasaki H, Shiba A, Aga M, et al.
Sci Rep
. 2022 Mar;
12(1):5323.
PMID: 35351942
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in...